Veracyte Files 8-K on Financial Condition and Operations
Ticker: VCYT · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1384101
| Field | Detail |
|---|---|
| Company | Veracyte, Inc. (VCYT) |
| Form Type | 8-K |
| Filed Date | Feb 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, operations, 8-K
TL;DR
**Veracyte just dropped an 8-K on its financial results and operations, so keep an eye out for the details!**
AI Summary
VERACYTE, INC. filed an 8-K on February 22, 2024, reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing, under SEC File Number 001-36156, indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in South San Francisco, CA, with a business phone of (650) 243-6300, operates in medical laboratories.
Why It Matters
This 8-K filing provides an update on Veracyte's financial health and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a routine filing for reporting financial condition and operations, not indicating any immediate adverse events.
Key Numbers
- 001-36156 — SEC File Number (Identifies the company's filing with the SEC)
- 20240222 — Filing Date (Indicates when the 8-K was filed)
- 16 — Public Document Count (Number of documents included in the filing)
- 8071 — SIC Code (Standard Industrial Classification for Medical Laboratories)
- 1231 — Fiscal Year End (Company's fiscal year end date)
Key Players & Entities
- VERACYTE, INC. (company) — Registrant
- February 22, 2024 (date) — Date of Report
- 001-36156 (dollar_amount) — Commission File Number
- 6000 Shoreline Court , Suite 300 , South San Francisco , California 94080 (company) — Address of principal executive offices
- (650) 243-6300 (dollar_amount) — Registrant’s telephone number
FAQ
What is the purpose of this 8-K filing by VERACYTE, INC.?
This 8-K filing reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of February 22, 2024.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on February 22, 2024.
What is VERACYTE, INC.'s business address and phone number?
VERACYTE, INC.'s business address is 6000 Shoreline Court, Suite 300, South San Francisco, California 94080, and its phone number is (650) 243-6300.
Under which SEC Act and Section was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the Standard Industrial Classification (SIC) for VERACYTE, INC.?
VERACYTE, INC.'s Standard Industrial Classification is SERVICES-MEDICAL LABORATORIES [8071].
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-02-22 16:12:13
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share VCYT The Nasdaq Stock Market
Filing Documents
- vcyt-20240222.htm (8-K) — 29KB
- vcyt-02x22x20248xkearningsa.htm (EX-99.1) — 295KB
- vcytlogoa.gif (GRAPHIC) — 6KB
- 0001384101-24-000013.txt ( ) — 480KB
- vcyt-20240222.xsd (EX-101.SCH) — 2KB
- vcyt-20240222_lab.xml (EX-101.LAB) — 25KB
- vcyt-20240222_pre.xml (EX-101.PRE) — 13KB
- vcyt-20240222_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 22, 2024, Veracyte, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Veracyte, Inc. dated February 22 , 202 4 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 22, 2024 VERACYTE, INC. By: /s/ Rebecca Chambers Name: Rebecca Chambers Title: Chief Financial Officer Principal Financial Officer